Skip to main content

EUROGIN 2018

Our CEO, Vanessa Vankerckhoven, CTO, Koen Beyers and Clinical Affairs Associate, Tine Provinciael will attend the conference. Do come and talk to us to learn more on the Colli-Pee device which is suited for (home-based) volumetric collection of first-void urine allowing detection of the Human Papilloma Virus, a virus able to cause cervical cancer.

EUROGIN2018

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.